ME02867B - Nova jedinjenja - Google Patents
Nova jedinjenjaInfo
- Publication number
- ME02867B ME02867B MEP-2017-188A MEP2017188A ME02867B ME 02867 B ME02867 B ME 02867B ME P2017188 A MEP2017188 A ME P2017188A ME 02867 B ME02867 B ME 02867B
- Authority
- ME
- Montenegro
- Prior art keywords
- pirolo
- amin
- butil
- pirimidin
- pentil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 20
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- JNSVNACCUJRHFR-UHFFFAOYSA-N 2-butyl-7-(5-pyrrolidin-1-ylpentyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine Chemical compound C12=NC(CCCC)=NC(N)=C2NC=C1CCCCCN1CCCC1 JNSVNACCUJRHFR-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (22)
1.Jedinjenje formule (I) ili njegova so gde R1 je n-C4-6alkil ili C1-2alkoksiC1-2alkil-; R2 je vodonik ili metil; svaki R3 je hidroksi, halo ili n-C1-3alkil; m je celi broj koji ima vrednost od 2 do 4; n je ceo broj koji ima vrednost od 0 do 3; p je ceo broj koji ima vrednost od 0 do 2.
2.Jedinjenje prema zahtevu 1, ili njegova so, gde je R1 n-butil.
3.Jedinjenje prema zahtevu 1, ili njegova so, gde je R1 etoksimetil.
4.Jedinjenje prema zahtevu 1, ili njegova so, gde je R1 2-metoksietil.
5.Jedinjenje prema bilo kom zahtevu 1-4, ili njegova so, gde je R2 vodonik.
6.Jedinjenje prema bilo kom zahtevu 1-4, ili njegova so, gde je R2 je metil.
7.Jedinjenje prema bilo kom zahtevu 1-6, ili njegova so, gde je n ceo broj koji ima vrednost 1 ili 2.
8.Jedinjenje prema bilo kom zahtevu 1-7, ili njegova so, gde je p 0.
9.Jedinjenje prema bilo kom zahtevu 1-7, ili njegova so, gde je R3 hidroksi ili halo.
10.Jedinjenje prema bilo kom zahtevu 1-7, ili njegova so, gde je p 1 i R3 je hidroksi ili fluoro.
11.Jedinjenje prema bilo kom od zahteva 1-7, ili njegova so, gde je p 2 i R3 je fluoro.
12.Jedinjenje prema zahtevu 1, ili njegova so, izabrano iz grupe koju čine: 2-Butil-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(piperidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(4-(piperidin-1-il)butil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-(Etoksietil)-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-(2-Metoksietil)-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(5-(piperidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(4-(piperidin-1-il)butil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(6-(pirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Pentil-7-(6-(piperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 7-(5-(Azepan-1-il)pentil)-2-butil-5H-pirolo[3,2-d]pirimidin-4-amin; 7-(4-(Azepan-1-il)butil)-2-butil-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(6-(pirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 7-(6-(Azetidin-1-il)heksil)-2-butil-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 7-(5-(Azetidin-1-il)pentil)-2-butil-5H-pirolo[3,2-d]pirimidin-4-amin; 7-(5-(Azetidin-1-il)pentil)-2-butil-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(4-(pirolidin-1-il)butil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(4,4-difluoropiperidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(4-fluoropiperidin-l-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 7-(5-(4-Fluoropiperidin-1-il)pentil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin; 1-(5-(4-Amino-2-butil-5H-pirolo[3,2-d]pirimidin-7-il)pentil)piperidin-4-ol; (R)-2-Butil-7-(5-(3-fluoropirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; (S)-2-Butil-7-(5-(3-fluoropirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; (R)-7-(5-(3-Fluoropirolidin-1-il)pentil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin; (S)-7-(5-(3-Fluoropirolidin-1-il)pentil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin; (S)-1-(5-(4-Amino-2-butil-5H-pirolo[3,2-d]pirimidin-7-il)pentil)pirolidin-3-ol; 1-(5-(4-Amino-2-butil-5H-pirolo[3,2-d]pirimidin-7-il)pentil)azetidin-3-ol; 7-(6-(Azepan-1-il)heksil)-2-(2-metoksietil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(6-(4-fluoropiperidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; (R)-2-Butil-7-(6-(3-fluoropirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; (S)-2-Butil-7-(6-(3-fluoropirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; (S)-2-Butil-7-(5-(2-metilpirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; (R)-2-Butil-7-(5-(2-metilpirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(3-metilazetidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(3-fluoroazetidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-6-metil-7-(6-(pirolidin-1-il)heksil)-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(4-fluoropiperidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; (S)-2-Butil-7-(5-(3-fluoropirolidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; (R)-2-Butil-7-(5-(3-fluoropirolidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; 2-Butil-7-(5-(3-fluoroazetidin-1-il)pentil)-6-metil-5H-pirolo[3,2-d]pirimidin-4-amin; i 2-(2-Metoksietil)-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin.
13.Jedinjenje prema zahtevu 1, koje je 2-butil-7-(5-(pirolidin-1-il)pentil)-5H-pirolo[3,2-d]pirimidin-4-amin ili njegova so.
14.Jedinjenje prema bilo kom od zahteva 1-13, koje je u obliku farmaceutske prihvatljive soli.
15.Jedinjenje prema bilo kom od zahteva 1-13, koje je u obliku slobodne baze.
16.Farmaceutska kompozicija koja sadrži jedinjenje koje je definisano prema bilo kom od zahteva 1-13, ili njegova farmaceutski prihvatljiva so, i jedan ili više farmaceutski prihvatljivih ekscipijenata.
17.Kompozicija vakcine koja sadrži jedinjenje definisano prema bilo kom od zahteva 1-13, ili njegovu farmaceutski prihvatljivu so i antigen ili antigenu kompoziciju.
18.Jedinjenje definisano prema bilo kom od zahteva 1-13, ili njegova farmaceutski prihvatljiva so za upotrebu u terapiji.
19.Jedinjenje koje je definisano prema bilo kom od zahteva 1-13, ili njegova farmaceutski prihvatljiva so, za upotrebu u lečenju alergijskog odgovora i drugih inflamatornih stanja, infektivnih bolesti i kancera.
20.Jedinjenje koje je definisano prema bilo kom od zahteva 1-13, ili njegova farmaceutski prihvatljiva so, za upotrebu u lečenju alergijskog rinitisa.
21.Jedinjenje koje je definisano prema bilo kom od zahteva 1-13, ili njegova farmaceutski prihvatljiva so, za upotrebu u lečenju astme.
22. Upotreba jedinjenja definisanog prema bilo kom od zahteva 1-13, ili njegove farmaceutski prihvatljive soli, u proizvodnji leka za lečenje alergijskih bolesti i drugih inflamatornih stanja, infektivnih bolesti i kancera.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728390P | 2012-11-20 | 2012-11-20 | |
| US201361774087P | 2013-03-07 | 2013-03-07 | |
| EP13857477.7A EP2922549B1 (en) | 2012-11-20 | 2013-11-18 | Novel compounds |
| PCT/US2013/070472 WO2014081645A1 (en) | 2012-11-20 | 2013-11-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02867B true ME02867B (me) | 2018-04-20 |
Family
ID=50776485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-188A ME02867B (me) | 2012-11-20 | 2013-11-18 | Nova jedinjenja |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9540383B2 (me) |
| EP (1) | EP2922549B1 (me) |
| JP (1) | JP6228223B2 (me) |
| KR (1) | KR20150085055A (me) |
| CN (1) | CN104780922B (me) |
| AU (1) | AU2013348218B2 (me) |
| BR (1) | BR112015011400A8 (me) |
| CA (1) | CA2892218A1 (me) |
| CL (1) | CL2015001342A1 (me) |
| CR (1) | CR20150268A (me) |
| CY (1) | CY1119557T1 (me) |
| DK (1) | DK2922549T3 (me) |
| DO (1) | DOP2015000121A (me) |
| EA (1) | EA028480B1 (me) |
| ES (1) | ES2639789T3 (me) |
| HR (1) | HRP20171150T1 (me) |
| HU (1) | HUE13857477T2 (me) |
| IL (1) | IL238800B (me) |
| LT (1) | LT2922549T (me) |
| ME (1) | ME02867B (me) |
| MX (1) | MX358025B (me) |
| NZ (1) | NZ707319A (me) |
| PE (1) | PE20151086A1 (me) |
| PH (1) | PH12015501100B1 (me) |
| PL (1) | PL2922549T3 (me) |
| PT (1) | PT2922549T (me) |
| RS (1) | RS56233B1 (me) |
| SG (1) | SG11201503282RA (me) |
| SI (1) | SI2922549T1 (me) |
| SM (1) | SMT201700378T1 (me) |
| UA (1) | UA114645C2 (me) |
| WO (1) | WO2014081645A1 (me) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| AU2012289042A1 (en) | 2011-07-22 | 2014-03-13 | Glaxosmithkline Llc | Composition |
| MX359671B (es) | 2012-08-24 | 2018-10-05 | Glaxosmithkline Llc Star | Compuestos de pirazolopiridina. |
| PL2922549T3 (pl) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nowe związki |
| CA2890201A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| WO2014081643A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| WO2015124591A1 (en) * | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon |
| MX386981B (es) * | 2014-08-15 | 2025-03-19 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| TWI558709B (zh) * | 2015-10-07 | 2016-11-21 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions |
| CN108349982B (zh) | 2015-11-05 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| DE60118521T2 (de) | 2000-01-07 | 2006-10-12 | Universitaire Instelling Antwerpen | Purin derivate, ihre herstellung und verwendung |
| RU2269523C2 (ru) | 2000-04-28 | 2006-02-10 | Акадиа Фармасьютикалз, Инк. | Мускариновые агонисты |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| ATE478872T1 (de) | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
| KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
| US6713241B2 (en) | 2002-08-09 | 2004-03-30 | Eastman Kodak Company | Thermally developable emulsions and imaging materials containing binder mixture |
| ES2363766T3 (es) | 2002-08-21 | 2011-08-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibidores de nucleosidasas y fosforilasas de nucleosidos. |
| KR101111085B1 (ko) | 2002-09-27 | 2012-04-12 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 화합물 및 그 용도 |
| CN1816530A (zh) | 2003-07-01 | 2006-08-09 | 麦克公司 | 用于治疗高眼压症的眼用组合物 |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| ATE465742T1 (de) | 2003-09-05 | 2010-05-15 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
| UY28506A1 (es) | 2003-09-12 | 2005-04-29 | Basf Ag | 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales. |
| KR101494056B1 (ko) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| EP1728792A4 (en) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINVERBINDUNG |
| US8012964B2 (en) | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| HRP20090495T1 (hr) | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
| JP2007537296A (ja) | 2004-05-14 | 2007-12-20 | アボット・ラボラトリーズ | 治療薬としてのキナーゼ阻害薬 |
| US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| MX2007013780A (es) | 2005-05-04 | 2008-02-05 | Pfizer Ltd | Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c. |
| NZ540160A (en) * | 2005-05-20 | 2008-03-28 | Einstein Coll Med | Inhibitors of nucleoside phosphorylases |
| US7932257B2 (en) | 2005-07-22 | 2011-04-26 | Sunesis Pharmaceuticals, Inc. | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
| JP2009504803A (ja) | 2005-08-22 | 2009-02-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒアゴニスト |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| WO2007024944A1 (en) | 2005-08-25 | 2007-03-01 | Schering Corporation | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
| MX2008002414A (es) | 2005-09-02 | 2008-03-27 | Pfizer | 1h-imidazopiridinas sustituidas con hidroxi y procedimientos. |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| US20080269240A1 (en) | 2005-09-22 | 2008-10-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel Adenine Compound |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| EP1939198A4 (en) | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND |
| US20090105212A1 (en) | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| WO2007034916A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| JP2009528989A (ja) | 2006-02-17 | 2009-08-13 | ファイザー・リミテッド | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 |
| US8349850B2 (en) | 2006-03-28 | 2013-01-08 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| GB2438679A (en) | 2006-05-31 | 2007-12-05 | Sra Dev Ltd | Ultrasonic surgical tool having two modes of vibration |
| EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | purine analogs |
| WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
| PT2038290E (pt) | 2006-07-07 | 2013-12-10 | Gilead Sciences Inc | Moduladores de receptor do tipo toll 7 |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| EP2125792B1 (en) | 2007-02-19 | 2010-12-01 | GlaxoSmithKline LLC | Purine derivatives as immunomodulators |
| SI2132209T1 (sl) | 2007-03-19 | 2014-05-30 | Astrazeneca Ab | Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7) |
| JP5329444B2 (ja) | 2007-03-19 | 2013-10-30 | アストラゼネカ・アクチエボラーグ | Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物 |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| SI2170888T1 (sl) | 2007-06-29 | 2015-10-30 | Gilead Sciences, Inc. | Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7 |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| US20120121540A1 (en) | 2007-08-10 | 2012-05-17 | Franz Ulrich Schmitz | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections |
| PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| WO2010018131A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
| JP5519670B2 (ja) | 2008-08-11 | 2014-06-11 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
| WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
| WO2010018134A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Novel adenine derivatives |
| WO2010083725A1 (zh) | 2009-01-20 | 2010-07-29 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
| US9493465B2 (en) * | 2009-07-17 | 2016-11-15 | Victoria Link Limited | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase |
| TR201909600T4 (tr) | 2009-08-07 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Lipide edilmiş oksoadenin türevleri. |
| WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| ES2525826T3 (es) | 2010-02-10 | 2014-12-30 | Glaxosmithkline Llc | Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
| US9249087B2 (en) | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| US9139590B2 (en) * | 2011-02-04 | 2015-09-22 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| WO2012167053A1 (en) * | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| AU2012289042A1 (en) | 2011-07-22 | 2014-03-13 | Glaxosmithkline Llc | Composition |
| MX359671B (es) | 2012-08-24 | 2018-10-05 | Glaxosmithkline Llc Star | Compuestos de pirazolopiridina. |
| CA2890201A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| WO2014081643A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| PL2922549T3 (pl) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nowe związki |
| WO2015124591A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon |
-
2013
- 2013-11-18 PL PL13857477T patent/PL2922549T3/pl unknown
- 2013-11-18 CN CN201380060067.8A patent/CN104780922B/zh not_active Expired - Fee Related
- 2013-11-18 CA CA2892218A patent/CA2892218A1/en not_active Abandoned
- 2013-11-18 MX MX2015006375A patent/MX358025B/es active IP Right Grant
- 2013-11-18 SG SG11201503282RA patent/SG11201503282RA/en unknown
- 2013-11-18 SI SI201330751T patent/SI2922549T1/sl unknown
- 2013-11-18 ME MEP-2017-188A patent/ME02867B/me unknown
- 2013-11-18 WO PCT/US2013/070472 patent/WO2014081645A1/en not_active Ceased
- 2013-11-18 NZ NZ70731913A patent/NZ707319A/en unknown
- 2013-11-18 ES ES13857477.7T patent/ES2639789T3/es active Active
- 2013-11-18 LT LTEP13857477.7T patent/LT2922549T/lt unknown
- 2013-11-18 PT PT138574777T patent/PT2922549T/pt unknown
- 2013-11-18 EA EA201590684A patent/EA028480B1/ru not_active IP Right Cessation
- 2013-11-18 UA UAA201504354A patent/UA114645C2/uk unknown
- 2013-11-18 HR HRP20171150TT patent/HRP20171150T1/hr unknown
- 2013-11-18 JP JP2015542860A patent/JP6228223B2/ja not_active Expired - Fee Related
- 2013-11-18 RS RS20170841A patent/RS56233B1/sr unknown
- 2013-11-18 HU HUE13857477A patent/HUE13857477T2/hu unknown
- 2013-11-18 SM SM20170378T patent/SMT201700378T1/it unknown
- 2013-11-18 PE PE2015000637A patent/PE20151086A1/es active IP Right Grant
- 2013-11-18 US US14/443,932 patent/US9540383B2/en active Active
- 2013-11-18 EP EP13857477.7A patent/EP2922549B1/en active Active
- 2013-11-18 KR KR1020157015893A patent/KR20150085055A/ko not_active Withdrawn
- 2013-11-18 AU AU2013348218A patent/AU2013348218B2/en not_active Ceased
- 2013-11-18 BR BR112015011400A patent/BR112015011400A8/pt not_active Application Discontinuation
- 2013-11-18 DK DK13857477.7T patent/DK2922549T3/en active
-
2015
- 2015-05-13 IL IL238800A patent/IL238800B/en not_active IP Right Cessation
- 2015-05-18 PH PH12015501100A patent/PH12015501100B1/en unknown
- 2015-05-18 CL CL2015001342A patent/CL2015001342A1/es unknown
- 2015-05-20 CR CR20150268A patent/CR20150268A/es unknown
- 2015-05-20 DO DO2015000121A patent/DOP2015000121A/es unknown
-
2016
- 2016-12-06 US US15/370,211 patent/US9907847B2/en not_active Expired - Fee Related
-
2017
- 2017-08-24 CY CY20171100898T patent/CY1119557T1/el unknown
-
2018
- 2018-01-18 US US15/873,996 patent/US20180140695A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171150T1 (hr) | Novi spojevi | |
| RU2015117251A (ru) | Новые соединения | |
| TN2014000357A1 (en) | Heterocyclyl compounds | |
| NZ702458A (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| HRP20180202T1 (hr) | Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti | |
| EA201290631A1 (ru) | Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она | |
| NZ702571A (en) | 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors | |
| UA115671C2 (uk) | Нікотинова композиція | |
| MY171553A (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
| JO3108B1 (ar) | بيرروليدينونات أروماتية مخلطة مندمجة كمثبطات syk | |
| EA202090258A2 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| HK1211027A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
| RU2015116953A (ru) | Новые соединения | |
| JP2016500068A5 (me) | ||
| PH12015500063A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| MX2021002255A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| SI2895174T1 (en) | The prodrugs of the amino quinazoline kinase inhibitor | |
| GEP20207070B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2012000954A (es) | Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. | |
| EA201291401A1 (ru) | НОВЫЕ ПРОТИВОГРИБКОВЫЕ ПРОИЗВОДНЫЕ 5,6-ДИГИДРО-4-[(ДИФТОРЭТИЛ)ФЕНИЛ]-4H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА И 4-(ДИФТОРЭТИЛ)ФЕНИЛ-6H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА | |
| EA201791354A2 (ru) | Препараты производных пиримидиндиона |